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Ethics committee responds
to professional and patient concerns

Looking for solutions to ethical
problems in the clinic
I

Ethics

Rebecca Pentz is a clinical
ethicist and associate
professor of clinical ethics
in the Office of the Vice
President for Patient Care

Some terminally ill patients favor the right to
die. Others demand heroic, extraordinary care to
stave off death as they await a medical miracle. As
medical technology creates support systems that
can sustain life when there is no hope of recovery,
physicians find themselves confronting choices that
depend far more on moral values than on medical
knowledge. Is it right to use a ventilator to prolong
a painful death? Is it right to let a patient terminally
ill with AIDS die of a curable pneumonia? To help
physicians serve patients and protect their patients'
rights, Rebecca Pentz, Ph.D., clinical ethicist at
The University of Texas M. D. Anderson Cancer
Center, trained a Clinical Ethics Committee to
provide counsel in tough situations.
Clinical ethics, a relatively new field, is a discipline that examines the ethical implications of
medical decisions in very practical situations. Physicians are trained to evaluate what is best for a
patient from a medical standpoint-predicting the
probable course of a disease and the chance for the
patient's recovery. Although a concern for ethics
has always governed the obligations of physicians,
Pentz pointed out that clinical ethics can help
physicians apply bioethical principles to modern
dilemmas. These principles mandate the use of
medical treatments that provide more benefit than
burden to the patient, the right of the patient to
decide for or against any-medical treatment, tlTe
right for a legal substitute to determine treatment
for a patient who lost or never had autonomy, and
the duty of health care professionals to act with
fairness in giving every individual judicious care.

Code of Ethics
In 1982, Charles LeMaistre, M.D., president of
M. D. Anderson Cancer Center, appointed a committee, co-chaired by Jan van Eys, M.D., and

James Bowen, Ph.D., to begin development of a
code of ethics. Two years later, after input from
employees, patients, and patients' families, M. D.
Anderson became the first major cancer center to
adopt a set of ethical principles as a standard against
which professionals could evaluate medical and
nonmedical decisions. The goal guiding these principles is the care of patients with cancer in an
environment dedicated to the prevention and eradication of the disease.

Clinical Ethics Committee
M. D. Anderson was one of the first institutions
in which policies for managing patients with endstage disease evolved. According to Michael S.
Ewer, M.D., associate professor of medicine in the
Cardiology Section, Department of Medical Specialties, "Because of the desire not to burden patients or families in cases of medical futility,
mechanisms for removing terminally ill patients
from life support systems were evolved in the intensive care unit in the early 1980s." Ewer, as
medical director of the intensive care unit, proposed in 1989 that a "decision triangle" be used to
balance the desires of patients and families, the
recommendations of a health care team, and the
medical appropriateness of a life support system.
When the argument for or against intervention
with a life supp-ort system is dear;-physician input
increases, but in the absence of a medical community consensus, patient and family input increases.
Lester J. Peters, M.D ., professor and head of the
Division of Radiotherapy, emphasized in an article
in Oncolog in 1990 that "unless a physician involves the patient in the decision-making process,
the physician may not be giving the patient the
treatment he really wants." Ethical problems cannot be solved within the walls of the clinic only.
continued on page 2
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" ... the very structure of the Clinical Ethics
Committee ensures that any specific question is
examined from several viewpoints."
For this reason, in June 199 3 M. D. Anderson
formed an expanded ethics committee to deal with
dilemmas in life-threatening situations, as well as
to provide institution and community education
and to revise ethically sensitive policies.
The standing ethics committee is an interdisciplinary group of 21 members: eight physicians,
eight nurses, and five allied health professionals
(one each from social work, patient advocacy, legal
affairs, chaplaincy, and inpatient management ser~
vices). Because of the multiple disciplines represented, the very structure of this committee ensures
that any specific question is examined from several
viewpoints. In addition to their professional training, each member of the committee completes
mandatory training in bioethics. Pentz outlined
the required training: "An in-depth knowledge of
the history of bioethics, the philosophy of bioethics, and the current literature must be mastered."
Working under the guiding principles introduced
by the 1984 Code ofEthics, three members of the
Clinical Ethics Committee are always on call and
can-within 20 minutes-consult with the health
care team round-the-dock concerning the ethical
principles of a case.
The committee examines the sorts of treatments available, the complications and risks involved, and the anticipated results on a case-by-case
basis. Although about three quarters of referrals to
the committee are initiated by physicians, other
health care workers or patients' families can refer a
decision to the committee. Ordinarily, both the
attending physician and the patient's nurse must
be present at the consulting session. The patient's
family must be present if a member of the family
has requested the advice, but the attending physician ma re uest that the atient's famil attend
any session.
Because health care providers encounter conflicts between value systems, the committee's goal
is to provide the tools necessary to clarify medical
and moral issues by proposing different ways of
thinking about the choices available. Pentz explained that M. D. Anderson's Clinical Ethics
Committee is trained to search for the best conduct in ethical dilemmas by approaching the choices
with a standard procedure. Dr. Pentz described the
process: "After gathering all the facts we can, we
first review the ethical principles that might apply
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to the case. If there are analogous cases, we also
review them. We state the options and weigh the
benefits and the burdens of each option. Then we
make a recommendation suggesting an option that
is best for this particular patient in this particular
circumstance."
Patient values guide committee's decisions
Religious, cultural, and family values are given
priority in the decision-making process of the committee. Thus, decisions that were previously the
sole responsibility of the physician are now shared
with the family. Because patients treated at M. D.
Anderson come from diverse geographic locations
and ethnic groups, physicians enc unter a wide
variety of cultural responses to life-threatening situations. Pentz explained: "Some individuals want
the physician to make the decisions in a life-threatening disease; others refuse to take advantage of
modern technology, even when they know it significantly lowers their risk; and some families want
both the hospital staff and the physician to lie to
the patient."
Patients' families do not always recognize the
physician's obligation to give complete information to very ill patients. These faJTtilies prefer to
protect their loved ones and so o bject to "truthtelling" in life-threatening circumstances. Pentz
said that studies have shown that patients do better
when they know the likely outcome of their disease, even when that outcome is a bad one. In one
study on Huntington's disease, the group that did
worst was the one composed.of patients in whom
genetic information was insufficient to determine
whether or not the disease would develop--even
worse than the group composed of those informed
that they would be victims of the disease. Because
of studies such as these, the Clinical Ethics Committee always errs on the side of truth. The exception would be when an individual, perhaps for
cultural reasons, autonomously chooses not to
know. "Even then we would have to be convinced
that the choice not to know the truth was autonomous," stated Pentz.
Avoiding futile or inappropriate care
Despite technological advances, clinicians have
no responsibility to offer or to provide treatments
that are not medically indicated. Pentz stated that
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although some patients and their families have
become more knowledgeable about their rights to
determine whether to accept a specific medical
treatment, they often lack essential medical knowledge and demand medical procedures that are
inappropriate for their disease. Although the physician sees the medical futility of a certain procedure, he or she is caught between the family's
wishes and medical expertise. The result of this
tug-of-war can be a patient who lies in a persistent
vegetative state. Pentz described the case of a
patient at another institution who remained alive
through resuscitation, ventilation, and artificial
hydration for 33 years. To avoid a similar situation,
the bioethics committee can mediate between
caregivers and families in decisions regarding medically futile treatments. As part of its policy responsibilities, the Clinical Ethics Committee is joining
a consortium of Houston hospitals to draft a policy
on medically futile and inappropriate care.
The difficulty of making life and death decisions
is magnified when patients are unable to speak for
themselves and surrogates must be consulted. To
represent the wishes of patients as accurately as
possible, M. D. Anderson's Clinical Ethics Committee assists in identifying the person most likely
to know the patient's intentions in a tragic circumstance. The legal surrogate, when not predesignated
by a durable power of attorney for health care by
the patient, is specified in order of priority by Texas
statute: first, a patient's spouse; next, an adult child
of the patient who has the waiver and consent of all
other adult children to make the decisions; a ma jority of the patient's reasonably available children;
the patient's parents; the individual the patient
clearly identified to act on his or her behalf before
the patient became incapacitated; the nearest living
relative; or, finally, a member of the clergy. The
legal surrogate, however, is not always the person
the attending physician feels speaks best for a pa tient. In one tragic case, Pentz related, the physician felt that the legal surrogate did not have the
atient's best interest in mind so an ethics consultation was called. The consultation team recommended that the health care team work on an
interim basis with the person who did best represent the patient, an ethical surrogate, while the
transfer of legal surrogacy was pursued.
Another frequent area of conflict is the area of
the living will. Living wills-although occasionally
designed to be specific-are usually very limited
documents that restrict extraordinary treatment
measures in a patient who is judged terminally ill
by two physicians when the disease is not reversible. "A family member," Pentz said, in describing

a hypothetical situation, "has suffered with a terminally ill patient, and when the patient contracts
pneumonia, the family member thinks enough is
enough and wants to withhold treatment. The
physician's medical expertise, however, judges that
pneumonia is a reversible disease that he is obliged
to cure." The ethics committee has frequently
been called to balance conflicting values in cases
such as these.
Other ethical concerns
The Clinical Ethics Committee also addresses
conflicts other than those involving patients. An
ethical question that arises frequently at M. D.
Anderson concerns the rights of minors selected as
bone marrow donors. Although bone marrow aspiration from the hip is considered to be a relatively
risk-free procedure, there is no direct benefit to the
donor. Because of the possibility of side effects in
donors, investigation into the value of an institutional policy that would require an automatic consultation by the Clinical Ethics Committee when
the donor is a minor is under way.
At times physicians refer cases to the committee
for advice when they are just unable to determine
the best ethical procedure. Pentz confirmed that
differences of opinion exist between professionals
concerning appropriate care. An example is whether
a surgeon should perform a resection if the results
are cosmetically unacceptable and the chance for
the patient's survival is only 10%.
Another area of ethical problems arises from the
funding or reimbursement policies of health management organizations and government agencies
that finance medical care. Limited resources produce questions of determining how much care is
available, who gets treated, and who decides which
procedures are necessary.
-LINDA N. EPPICH
Prior a_rticles published in Oncolog that describe
ethical issues are "Is Malpractice Litigation Undermining Informed Consent?" (Jan.-Mar. 1990, Vol.
35, No. 1) and "Decision Making in Critical Illness:
Who Knows Best?" (Jan.-Mar. 1991, Vol. 36, No.I).
Physicians who desire a copy of M. D. Anderson's
Code of Ethics or additional information may write
Dr. Pentz, Department of Clinical Ethics, Box 111,
The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, or
call(713) 794-5727. ■
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Prevention the ultimate goal

Colon cancer registry coordinates
treatment, education, and research
Cancer Registries

Linda Howard is a senior
research nurse in the
Department of Gastrointestinal Oncology and
Digestive Diseases
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Webster's Dictionary defines a registry as an
official record book. But a family medical registry
is more. "Our registry isn't a box of data-it's airtraffic control," said Linda Howard, R.N., B.S.N.,
coordinator of the Hereditary Colon Cancer Registry of The University of Texas M. D. Anderson
Cancer Center. "We try to identify those patients
at high risk for developing colon cancer so that we
can see that they receive the proper treatment,
counseling, and education. It's more holistic than
you would think." The M. D. Anderson registry
was formed in 1988 by its medical director, Patrick
M. Lynch, M.D., J.D., of the Department of Gastrointestinal Oncology and Digestive Diseases, and
comprises patients with two forms of hereditary
colon cancer (HCC): familial adenomatous
polyposis (FAP) and hereditary nonpolyposis colon cancer (HNPCC).
Because these diseases are inherited in an autosomal dominant fashion, children who have one
parent with either disease have a 50% chance of
having the disease themselves. Early detection can
mean the difference between life and death for
people who inherit the disease. "For the most part,
if you find colon cancer early, it's curable. If you
find it later, there is not much you can do. And any
patient who has oneofthe HCC genes and develops colon cancer is at high risk of developing other
forms of cancer," said Howard. The current method
of diagnosis is colonoscopy, a process too costly to
use to screen the general population but well worth
the price for people with HCC. "In FAP patients,
we cannot remove all the polyps we see by
colonoscopy, but we can watch them carefully and
dela removal of the colon which is the definitive
treatment of the disease," said Howard. "In
HNPCC patients, we can remove the occasional
polyps we see by colonoscopy, and we can offer
early medical and surgical intervention for the cancers we find."
The problem is identifying the people who have
HCC, which is one of the goals of the registry.
Colon cancer is the second most common cancer
in the U.S., but it is usually a disease of old age,
developed by people in their 60s or older. But like
most hereditary forms of common diseases, HCC
develops much earlier. The approximately 6% of

colon cancer patients with HCC can begin to
develop polyps as early as puberty.
Because physicians are not used to seeing young
patients with colon cancer, these patients often go
undiagnosed. "Many of these people have had
symptoms for a long time, but their doctors never
think to do colonoscopy, because the patients are
'not old enough' to have colon cancer," said
Howard. "A big job that we have, both within
M. D. Anderson and externally, is to educate physicians and all kinds of health care workers about
the specifics of high-risk patients." Lynch and
Howard spread the word about the M. D. Anderson registry and about recent advances in colon
cancer treatment and research through the HCC
Newsletter) a quarterly bulletin pu blished by M. D.
Anderson. The newsletter reaches about 2500
physicians, researchers, and patients worldwide.
A recent issue of HCC Newsletter described the
cloning of the genes for FAP and HNPCC, which
Howard said has made identifying people with
HCC both easier and more confusing. "Since there
has been a lot in the papers about the colon cancer
.genes, there's a lot of misunderstanding about
who can be tested and what the tests can reveal,"
she said. There are no 100% accurate genetic tests
for FAP or HNPCC. If both a parent and child
with colon cancer have the same change in their
colon cancer genes, the genetic change probably
caused the cancer. Some genetic changes do not
cause disease, however, and whether this is true for
colon cancer has not been confirmed. (For more
information on genetic testing and other registries,
see "Familial cancer syndromes a focus of cancer
enetics research " M. D. Anderson Oncolo J -=u=l..yL_-_ _
September 1994.) Currently about half of the index cases (first patients identified in each family) in
the M. D. Anderson registry have undergone genetic testing for HCC.
How patients and others use the information
they receive from genetic tests can cause problems.
"One patient was denied the opportunity to upgrade a life insurance policy. It was one that he had
upgraded every year or two, but this time his
insurance company refused because he had
HNPCC." Because of the possibility of such repercussions, the fact that a patient has been diagnosed
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as having HCC by genetic tests is not put on
patient records at M. D. Anderson. "We say that
their families are being evaluated," said Howard,
"and the information will not be given to a physician without the consent of the patient."
Referrals to the M. D. Anderson registry come
from all sorts of people and places. M. D. Anderson surgeons and pediatricians refer their young
patients with colon cancer, as do physicians outside
M. D. Anderson who think that their patients may
have a hereditary form of colon cancer. And some
patients simply call the main switchboard themselves and are referred to Howard or Lynch. The
registry currently contains about 125 families with
confirmed hereditary colon cancer and another 50
that are being assessed. The largest has 164 members. "I know people in that family who don't
know each other," said Howard with a laugh. "I've
watched one set of kids grow up."
Howard's first step in assessing whether a family
has HCC is to gather information on who in the
family has colon cancer and to construct a pedigree, or family tree. She estimates that gathering
this initial information for the average family of
one colon cancer patient and five relatives takes an
average of30 hours. It is time well spent, however,
because even without genetic tests Howard and
Lynch can often determine from the pedigree alone
who in the family has an elevated risk of developing
colon cancer. Studies have shown that if a person
has one first-degree relative (parent, child, sister, or
brother) with colon cancer, the person's probability of developing colon cancer is 3% greater than
that of people without a first-degree relative with
colon cancer. If an individual has two first-degree
relatives with colon cancer, the probability is 17%
greater, and yearly colonoscopy is recommended.
To meet the broad range of needs of families
with HCC, Lynch and Howard can call on many
clinical and research professionals at M. D. Anderson, including John M. Skibber, M.D., of Surgical
Oncology and Ayten Cangir, M.D., of Pediatrics
tment· Bernard Levin M.D.
vice president for cancer prevention, for suggestions on how to prevent colon cancer; Walter Baile,
M.D., of Psychiatry and Ellen Gritz, Ph.D., of
Behavioral Science for counseling; Susan Peterson,
M.P .H., of Patient Education for educational assistance; and Marsha Frazier, Ph.D., of Gastrointestinal Oncology and Digestive Diseases for genetic
testing. In turn, the patients can volunteer to participate in HCC research. The M. D. Anderson
registry serves as a source of cases for clinical trials
of colon cancer treatment being conducted at M. D.
Anderson. One trial is testing the usefulness of

sulindac, a nonsteroidal anti-inflammatory drug
originally used to treat arthritis. Its efficacy against
colon cancer was discovered by chance: when FAP
patients took sulindac for arthritis, their polyps
regressed too, delaying the need for surgery.
The knowledge that Howard and Lynch have
about HCC and what resources are available for
HCC patients extends outside M. D. Anderson.
For instance, Howard recently assisted a family
from Missouri. "It was a nightmare," she said.
"They had just moved to Missouri and had no
money and no insurance, and they weren't eligible
for Medicaid. The woman's husband had died of
colon cancer caused by FAP. He had had no family
history of colon cancer but apparently had the gene
for it." (Because the gene is highly mutable, said
Howard, this is not unusual.) "The woman had
her 15-year-old son tested with colonoscopy, and
he had it, and his doctors immediately suggested
surgery. But the only procedure being performed
in their town was complete colonectomy with an
ileostomy, which is pretty traumatic for anyone of
any age, much less a 15-year-old. So his mother
called M. D. Anderson to see if any other procedures were available anywhere. I canvassed the
people in our department and the Division of
Surgery and identified physicians in Kansas City.
The woman ended up taking her son there, where
he had less radical surgery performed."
Howard stressed that this is the value of the
registry-matching resources with the people that
need them, taking into account their individual
wants. "Family dynamics can be a problem, because every family is unique. The way you contact
people, the way you handle people has to be a little
different in each case. That's the one thing a family
registry can do for a family doctor-offer expertise
and support. We'd like to become more involved
in the grass roots of primary care. Part of the
mission of M. D. Anderson is to educate and to
support prevention. And this is the ultimate form
of prevention."
ODE

Physicians who desire additional information may write
Ms. Howard or Dr. Lynch, Department of Gastrointestinal Oncology and Digestive Diseases, Box 78, The
University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Blvd., Houston, Texas 77030, or call
Ms. Howard at (713) 794-5451 or Dr. Lynch at (713)
792-2828. To receive the HCC Newsletter, call the
M. D. Anderson Department of Scientific Publications at (713) 792-3305. ■
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"Interferon is just one piece of the
whole tumor suppression puzzle."

Interferon
continued from page 8

clinically significant entity. Gutterman compares
these cancers with cardiovascular disease: both have
early signs that, if detected and corrected, may
prevent serious disease later on. "Although th_e
biology of the two appear unrelated, they have
subtle similarities· furthermore, both begin with a
clinically undete;table genetic defect that causes
progressive damage and leads over 20 or 30 years
to a serious, even fatal, medical condition. Like
cardiovascular disease, cancer is exacerbated by
environmental factors, which accelerate the rate of
conversion of the altered or damaged cells to malignancy." Furthermore, the similarities between
the two are the key to early detection of cancer:
Gutterman foresees a method of measuring early
signs of cancer, that is, the abnormal genes, as
blood pressure measurement now detects the early
signs of cardiovascular disease.
The abnormal genes that cause cancer comprise
at least three types: oncogenes, which, when altered, encourage the abnormal growth and division that characterize cancer; tumor suppressor
genes, which, when altered, fail to control this
abnormal growth and division; and the newly discovered DNA repair genes, which, when altered,
fail to repair mutations that can lead to cancer.
Researchers believe that there are about 30 to 40
tumor suppressor genes in the body, each of which
produces a protein, and they are starting to believe
that these proteins are controlled by "master" tumor suppressor proteins such as Rb (for retinoblastoma with which it was first associated and 53
(associated with many different tumors). Evidence
from the laboratory suggests that returning just
one of these tumor suppressor genes to its normal
function can appreciably reduce the aggressiveness
of the malignancy if not stop the growth.
Gutterman became intrigued by interferon when
it was discovered to inhibit cell growth; it was also
known to have certain positive effects on the immune system. He now considers it analogous to a
tumor suppressor protein: it inhibits the growth of
cells, particularly malignant cells, it blocks the effects of many oncogenes and growth factors, and
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unlike other biological agents, it inhibits cell motility ( cell motility is critical to the process of
metastasis). Gutterman suspects that this inhibition of cell motility is at least as important as the
inhibition of cell growth in stopping the growth of
cancer.
Cells are embedded in the extracellular matrix,
which comprises fluids, proteins, micromolecules,
and other substances around the cells and allows
the cells to communicate with each other. Controlling this communication are cytokines, which
are secreted by cells into the plasma and extracellular matrix. They work rather like a neighborhood
cop (in Gutterman's words) to keep the cells and
their extracellular environment in a balanced, homeostatic state.
Intercellular communication is dependent on
the proper functioning of all the structural components of the tissue through which the messages are
conveyed: the matrix, the cell membrane, the
cytoskeleton, and the cell itself. In cancer, the
communication network between cells is disrupted.
If the cytoskeleton is disrupted, the messages don't
get through to the nucleus and the nucleus begins
to function abnormally. Since the nucleus is the
site where the oncogenes or tumor suppressor
genes get switched on or off, this abnormal functioning can lead to malignancy. When this happens, the cells start growing irregularly and do not
differentiate. They may start to move and disrupt
other cells. Gutterman believes that interferon,
probably in concert with other extracellular and
cellular substances, restores the balance, the homeostasis, making sure the messages get through
properly. It stops growth, stops motility, and enhances the ability of the cell, through adhesion
molecules to res ond to its environment. It corrects defects, injuries, in the cytoskeleton. Interferon has also been found to block angiogenesis,
the initial step in the formation of new blood
vessels that is essential to the growth of malignancies. Moreover, it blocks fibrosis, a response to
injury that stimulates many different kinds of cells
and promotes cell growth.
Traditional chemotherapy has taken the approach
of interrupting the functioning of cells, especially
division, with little attention to the surrounding
structures. The success of this strategy in most
cancers may have been limited, suggested
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Gutterman, because it does not address this disruption of the extracellular environment.
Tumor suppressor proteins Rb and p53 work
within the cell to regulate the cell cycle. Interferon,
working outside the cell, is believed to induce and
regulate Rb (its relationship with pS 3 is not well
understood). Gutterman believes that interferon
may, in concert with the tumor suppressor proteins
inside the cell, mediate the tumor suppressor function, and that the protein inside the cell cannot be
totally effective without adequate interferon outside the cell. He speculates that attempts to stop
cancer by replacing defective tumor suppressor
genes with functioning genes that will produce the
effective tumor suppressor protein in the cells might
be successful only if extracellular levels of proteins
such as interferon are adequate.
Although aging and certain environmental insults such as cigarette smoking may deplete interferon levels, inadequate levels of interferon cannot
be remedied by simply administering the protein
to the body. For one thing, interferon is toxic in
pharmacologic doses. Fortunately, technology can
provide solutions: interferon can be administered
in tiny physiologic doses that are effective but not
toxic; interferon analogues can be synthesized that
suppress tumor growth without toxic effects; or
endogenous production of interferon can be induced or increased by gene therapy. For this reason, Gutterman sees cytokine biology as an
important emerging field. He is quick to say that
he does not see interferon as a cure-all for cancer,
but that the way researchers are looking at the
protein is changing: "We are asking totally different questions than we did 15 years ago."
Chemoprevention of cancer may be one application of interferon if the problems with toxicity
and route of administration can be solved. Only
oral agents are feasible for large population-based
chemoprevention trials, and right now interferon is
administered only by injection. One form of interferon, interferon -alpha, has been used in a few

the protein can be very effective in very early stage
disease. He says that we will have to change the
way we think about biological agents: biologicals
and chemotherapy are very different approaches
and should not be evaluated in the same ways.
They may be effective in stopping or stabilizing
cancers, not in shrinking large tumors.
Gutterman is especially excited about two areas
of research now active at M. D. Anderson. One is
the search for inhibitors of angiogenesis; one of the
most promising is a fungus called fumagillin, which
has the potential to act synergistically with interferon, limiting the proliferation of tumor cells. The
combination is being tried in patients with prostate
cancer, but the studies are still at very early stages.
The other area, the combination ofinterferon with
replacement of abnormal tumor suppressor genes,
is still in the laboratory, although the researchers
hope to have a clinical protocol under development soon. This reflects the new way of thinking
of interferon as an extracellular tumor suppressor
protein. It is probable that interferon will not work
to suppress tumors on its own, but will be used
with the replaced tumor suppressor protein in place
to inhibit tumor growth. "Interferon is just one
piece of the whole tumor suppression puzzle,"
affirmed Gutterman.
Gutterman believes that the interrelationship of
carcinogenesis, angiogenesis, and fibrosis in cancer
development suggests that cancer is the result of an
injury to tissues or cells. In the way the body
responds to them, tumors are in some ways very
like wounds, and interferon heals them: it stops the
cells from moving around, it stops the fibrosis, it
stops the blood vessels, it stops the growth.
Gutterman feels certain that, given time, we will be
able to harness these qualities and use them to stop
the growth of cancer.
-KATHRYN L. HALE
Physicians who desire more information may write to
Dr. Gutt€rman, Department of Clinical Immunology
d B· 1 · al Th
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occurring and synthetic analogues of vitamin A
that are known to have inhibitory effects on cancer
development. The results were encouraging in that
interferon did appear to have a potentiating effect
on the retinoids.
Interferon is in a period of transition. Gutterman
believes that cancer researchers are going to have
to start looking at new ways of treating cancers and
assessing what constitutes an effective drug. His
work has indicated that interferon is not effective in
advanced cancers. If he'd been discouraged and
stopped there, he never would have learned that

Texas M . D. Anderson Cancer Center, 1515 Holcombe
B1vd ·, HouS t0 n, Texas 77 o3 o, or call ( 713 ) 792 2676. ■
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Taking a new look at cytokine biology

Interferon: the evolution of a
biological therapy
Treatment Update

Jordan Gutterman is
chairman of the
Department of Clinical
Immunology and
Biological Therapy

When interferon was discovered in 1957, it was
hailed as a significant antiviral agent. In the late
1970s, interferon made a big splash as a symbol of
recombinant gene technology and the medical
breakthroughs it would bring. Fifteen years later,
interferon is a symbol of something quite different-the complexity of the biological processes of
cancer and the value of endurance and persistence
in tackling this complexity.
Jordan Gutterman, M.D ., chairman of the Department of Clinical Immunology and Biological
Therapy, The University of Texas M. D. Anderson
Cancer Center, was one of the foremost experts on
the then little-known interferon when it became an
"overnight sensation" in 1980 as one of the first
proteins to be produced by recombinant gene
technology. Having witnessed the evolution of
interferon's status, Gutterman has seen firsthand
how progress in the understanding of cancer biology comes not through big breakthroughs but
through the steady accumulation of discoveries.
Recalled Gutterman, "In 1980, the public perception of interferon was as a big breakthrough, but it

wasn't a sudden thing. It was m rel on
ent in
the long process of learning verything we can
about the protein's role in cancer o that
can
determine its clinical applications. It is thi teady
progress toward elucidation that is citing and
leads to innovation. Discovery is onl th fir t
step-development is a much more delib rate, longterm endeavor.
"Interferon wasn't appro ed by the U.S. Food
and Dru Administration for clinical use until 1986
nearly 30 years after its disco ery. Because of the
expense and duration of the drug de elopment
process, fewer anticancer agents will be de eloped
for the clinic in the future. To help us choose the
drugs with the greatest potential, e need to improve our understanding of the underlying ph siological e ents leading to cancer. '
Gutterman belie es that information gained from
the study of interferon in the last 15 ears has
opened the door to a new a of thinking about
cancer-as a chronic disease. With a few e ceptions, cancers, including the epithelium-deri ed
adult carcinomas, take man ears to e ol e into a
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